2Young SD, Britcher SF, Tran LO, et al. L-743,726( DMP-266 ): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1reverse transcriptase [ J ]. Antimicrob Agents Chemother,1995,39 (12) :2602 - 2605.
3Bellarosa D, Antonelli G, Bambacioni F, et al. New arylpyrido-diazepine and thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase [J]. Antiviral Res, 1996,30:109 - 124.
4Corbett JW, Ko SS, Rodgers JD, et al. Expandedspectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1 [ J ]. Antimicrob Agents Chemotner, 1999,43(12): 2893 -2897.
6Ludovici DW, Kavash RW, Kukla M J, et al. Evolution of anti-HIV drug candidates. Part 3: diaryipyrimidine (DAPY) analugues [J]. Bioorg Med Chem Lett, 2001,11:2235 - 2239.
7Rao A, Carbone A, Chimirri A, et al. Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4- ( thi ) one derivatives [ J ]. Il Farmaco , 2002,57:747 - 751.
8Rao A, Carbone A, Chimirri A, et al. Synthesis andanti-HIV activity of 2, 3-diaryl-1, 3-thiazolidin-4-ones [J]. Il Farmaco , 2003,58:115 -120.
9Vig R, Mao C, Venkatachalm TK, et al. Rational design and synthesis of phenethyl-5 -bromopyridyl thiourea derivatives as potent non-nucleoside inhibitorsof HIV reverse transcriptase [ J ]. Bioorg Med Chem, 1998,6:1789 - 1797.
10Balzarini J, Brouwer WG, Felauer EE, et al. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1strains [J]. Antiviral Res, 1995,27:219 -236.
